88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) (88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF)) told investors that third-party mapping work in Alaska is now complete.
The company’s consultant Jordan & Pay evaluated the Shelf Margin Delta (SMD), Slope Fan Set (SFS) and Basin Floor Fan (BFF) play fairways across the Project Icewine acreage on Alaska’s North Slope.
Tower Resources PLC (AIM:TRP) said it is redrawing its funding plans for drilling the NJOM-3 well at the Thali project, offshore Cameroon to give a less dilutive outcome for shareholders.
A planned farm-out of 49% to Beluga Energy for US$15mln has been shelved with a new proposal being worked on by all the parties, said a statement from the junior.
Quadrise Fuels International PLC (AIM:QFI, OTC:QDRSF), the supplier of alternative fuels, believes it is on course to commercialisation targets following positive engagement with counterparties in recent weeks.
The company’s board recently completed a review of the company’s projects, operations and business development activities, the upshot of which was that the company intends to progress with each of its core projects as well as with the development of bioMSAR fuel and its derivatives.
Iofina PLC (AIM:IOF, OTC:IOFNF) announced its fourth consecutive year of record revenues and underlying earnings (EBITDA), with pre-tax profits quadrupling.
The specialist in the exploration and production of iodine saw revenue in 2021 rise by 31% to US$39.0mln from US$29.7mln in 2020.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) said it had picked up an optical technology that will "play a key role in the future of modern vehicles".
It is paying A$5mln over three years to acquire a worldwide perpetual licence from an unnamed start-up that it hopes will lead to a step-change in the performance of cabin monitoring technology.
NextEnergy Solar Fund Ltd (LSE:NESF) has made its second international co-investment, taking a stake in a solar project in Portugal.
The company is paying around €22.5mln to NextPower III ESG for a 13% stake in a 210-megawatt project under construction in Santarém.
A leading academic journal has published research that burnishes the potential of Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF)’s lead cancer drug, bexmarilimab.
The article in American Association for Cancer Research publication, Molecular Cancer Therapeutics, focuses on the Clever-1 protein and explores the hypothesis it should be the target for the next generation of immunotherapies.